The European market for transcatheter embolization and occlusion (TEO) devices
consists of devices for both the interventional neuroradiology (INR) and
peripheral vascular (PV) indications. Both markets will grow moderately over
the forecast period, bolstered by the adoption of premium-priced devices. In
the INR space, premium-priced flow-diverting devices will capture share from
INR embolization coils and coiling-assist devices for the treatment of
intracranial aneurysms, which will increase TEO device revenues overall. INR
flow-diverting devices will also boost revenue by expanding the treatable
patient population, leading to increased procedure volumes. In the PV space,
the high incidence of hepatocellular carcinoma (HCC) and metastatic colorectal
cancer in Europe will drive growth in PV TEO device use. Furthermore, the
availability of innovative, premium-priced devices such as drug-eluting beads
and radioembolization spheres will boost revenues, while focusing industry and
physician interest on these indications. The European TEO device market will,
however, be limited by the availability of competing treatments, such as
surgical clipping for intracranial aneurysms and surgical hysterectomy and
myomectomy for uterine fibroids. Despite this competition, the European TEO
device market will experience steady growth through 2016.
This report uses a number of methodologies to gather and present data and
analysis. At the outset, a large survey of secondary sources is conducted.
These sources act as the basis for the primary research stage, which builds
and enhances the quantitative and qualitative attributes of the early research.
Secondary sources include
Securities and Exchange Commission filings
Food and Drug Administration and patent filings
French Ministry of Health
Germany Department of Statsistics
Italian Ministry of Health
National Health Service, UK
Transcatheter embolization and occlusion (TEO) device companies:
Annual reports, product brochures, corporate profiles, etc.
Internal databases and reports:
Previous reports on similar/related sources
General Internet searches, medical literature, and newspaper/magazine
Identifying various centers of specialization and articles that might
provide leads for primary research
The secondary research stage builds the foundation for the primary research.
The primary research methodology has four steps:
Step 1: The first step involves an impartial scan of all the
information gathered during the secondary research stage to determine its
utility based on the specific requirements of this report. Each piece of
information is either discarded or marked as high- or low-priority and then
organized appropriately as determined by the structure and sectioning of the
Step 2: At this stage, early assumptions are formed as to the
implications of the information for the various TEO device market segments.
These assumptions are then used to determine hypotheses using both inductive
and deductive approaches. On the quantitative front, these hypotheses result
in full historical and projected market data sets (market sizes - unit sales,
average selling prices [ASPs], and revenues - as well as market shares).
Step 3: At this stage, the research is in position for its most
important primary phase - expert interviews. Throughout the secondary research
phase, industry and medical experts are identified.
These experts are then contacted by telephone and asked to participate in
interviews on recent trends and developments in the industry. Interviews are
either conducted at the time of the initial call or scheduled at the
convenience of the expert. Interview questions are tailored to the expertise
of each particular interviewee, although in most cases, the most important
questions are asked of all experts.
The questions are largely based on the assumptions and hypotheses developed in
Step 2, which are then augmented, discarded, or adjusted based on the views
and positions put forth. Attempts are made, whenever possible, to cross-check
the views of various experts against each other and to reach positions of
consensus on issues and market numbers.
Step 4: The final stage of primary research involves individual and
group analysis by Millennium Research Group. All research results are assessed
and cross-checked thoroughly to determine their validity, relevance, and
weight. From this process, qualitative conclusions are reached and data points
Millennium Research Group's Marketrack methodology involves recruiting
hospital personnel responsible for the management of medical equipment and
procedures to participate by providing procedure volumes, device usage data,
and brand-level pricing information on an ongoing basis.
Hospital respondents include facility managers, nurses, administrators, and
physicians. For Millennium Research Group's European Interventional Radiology
Marketrack project, information is collected from 40 facilities in Europe on a
quarterly basis, including, but not limited to, numbers and types of
procedures performed and devices used.
In addition to the research methodology outlined above, the following
“bottom-up” methodology is used to develop forecast assumptions
for the report.
A comprehensive breakdown of various TEO device procedures and unit sales is
prepared using data from several sources, including professional associations,
government statistics, and private research/media sources. Industry experts
and practitioners are consulted to ensure accuracy and verify observed trends.
As a cross-check, total industry revenues available through annual reports and
other sources are compared against modeled industry revenues.
Using the best estimates of industry experts, practitioners, private
research/media sources, and inhouse experts, year-by-year growth rates and
ASPs are applied individually to each subcategory to derive forecasts. These
estimates are cross-checked by industry experts (marketing managers, product
managers, CEOs, etc.) and further refined.
Overall findings are compared against market and procedure forecasts published
by other sources to ensure reasonable estimates.
Companies mentioned in this report:
Biocompatibles (a BTG International company)
BioSphere Medical (a Merit Medical Systems company)
Codman & Shurtleff (a Johnson & Johnson company)
ev3 (a Covidien company)
MicroVention (a Terumo company)
St. Jude Medical
Table of Contents
Table of Contents
TABLE OF CONTENTS
LIST OF FIGURES AND TABLES
1.0 CLINICAL LANDSCAPE
1.1.1. Interventional Neuroradiology Indications
188.8.131.52. Intracranial Aneurysms
184.108.40.206. Cerebral Arteriovenous Malformations
220.127.116.11. Cerebral Arteriovenous Fistulas
18.104.22.168. Intracranial Hypervascularized Tumors
1.1.2. Peripheral Vascular Indications
22.214.171.124. Uterine Fibroids
126.96.36.199. Peripheral Vascular Aneurysms and Endoleaks
188.8.131.52. Hepatic Tumors
1.2. Diagnosis and Referral Patterns
1.2.1. Interventional Neuroradiology Indications
1.2.2. Uterine Fibroids
1.2.4. Peripheral Vascular Aneurysms and Endoleaks
1.2.5. Hepatic Tumors
1.3. Procedure Overview
1.3.1. Interventional Neuroradiology Transcatheter Embolization and
Table 288: PV Accessory Device Market, by Product Subtype, as a % of
Total, UK, 2010 - 2016
APPENDIX A: METHODOLOGY
Table 289: Average Currency Exchange Rates, 2011
APPENDIX B: MRG ACRONYMS AND INITIALISMS
MRG Acronyms and Initialisms
APPENDIX C: BIBLIOGRAPHY
European Markets for Transcatheter Embolization and Occlusion Devices 2012 published by Millennium Research Group in April 30, 2012. This report price starts from US $ 7195.
The contents of this page may be different from the latest version. Please contact us for details.
Radioembolization Spheres, Drug-Eluting Beads and Flow-Diverting Devices Drives Transcatheter Embolization and Occlusion Device Market Growth in Europe
May 17th, 2012
Global Information Inc. would like to present a new market research report, "European Markets for Transcatheter Embolization and Occlusion Devices 2012" by Millennium Research Group.
Adoption of premium-priced devices will drive market growth in the European transcatheter embolization and occlusion (TEO) market. Despite declining average selling prices in all device segments, market growth will outpace procedural growth, as newer, more expensive devices are used in place of more established devices. This will be particularly significant in the embolization particle and flow-diverting device segments.
Radioembolization has generated significant physician interest as a way of treating hepatocellular carcinoma as well as metastatic liver cancer in a targeted fashion. Across Europe, improved detection and screening has revealed large undertreated populations with both of these diseases. Combined with an increasing focus on innovative interventional oncology treatments, this will lead to increased volume of procedures using radioembolization particles and drug-eluting beads through 2016. The two main competitors in the European radioembolization particle market, Nordion and Sirtex Medical, are actively investing in clinical trials and marketing practices to drive awareness and gain reimbursement status for these devices.
Interventional neuroradiology (INR) flow-diverting devices are an effective new technology for treating intracranial aneurysms. These devices could represent a universal solution for the most difficult to treat aneurysm cases, such as fusiform, wide-neck, giant and multilobar aneurysms because they reconstruct the diseased portion of patients arteries without putting pressure on aneurysm walls. Premium-priced INR flow-diverting devices will thus see strong growth, partially at the expense of current treatments using INR embolization coils and coiling-assist devices.
"These innovative markets are attractive to new entrants," said MRG Analyst Louise Murphy. "The European INR flow-diverting device market, for example, is relatively small, with only two competitors, BALT Extrusion and ev3 (a Covidien company). But a number of devices with a similar neck-bridging concept are entering the market, Surpass Medical being the first example. These companies are promoting aggressively to drive adoption. We can expect to see a lot of volatility in their market shares through 2016."